Ironwood Pharmaceuticals | IRWD - Debt


Ironwood Pharmaceuticals reported $583.99M in Debt for its fiscal quarter ending in December of 2024.





Debt Change Date
Acadia Pharmaceuticals USD 52.19M 2.62M Dec/2025
Agios Pharmaceuticals USD 40.21M 4.31M Dec/2025
Akebia Therapeutics USD 46.51M 7.82M Mar/2025
Almirall EUR 342.86M 61.94M Dec/2025
Alnylam Pharmaceuticals USD 1.28B 30.06M Dec/2025
Amarin USD 0 0 Mar/2025
Ardelyx USD 207.61M 968K Sep/2025
Astellas Pharma JPY 831.43B 83.94B Mar/2025
AstraZeneca USD 33.92B 4.3B Mar/2026
Charles River Laboratories USD 2.57B 58.23M Dec/2025
Coherus Biosciences USD 294.92M 1.25M Mar/2025
Emergent BioSolutions USD 903.2M 495.2M Jun/2023
Esperion Therapeutics USD 262.92M 1.76M Sep/2024
Halozyme Therapeutics USD 2.14B 2.01M Mar/2026
Incyte USD 39.43M 982K Mar/2026
Ironwood Pharmaceuticals USD 583.99M 14.83M Dec/2024
Karyopharm Therapeutics USD 299.23M 35.14M Dec/2025
Lexicon Pharmaceuticals USD 99.51M 243K Dec/2023
MacroGenics USD 37.01M 238K Sep/2025
Moderna USD 1.31B 571M Dec/2025
Myriad Genetics USD 59.3M 19.7M Mar/2025
Pacira USD 367.66M 4.53M Mar/2026
PTC Therapeutics USD 286.94M 2.42B Mar/2026
Puma Biotechnology USD 89.06M 55.07M Jun/2024
Sarepta Therapeutics USD 1.04B 210.44M Dec/2025
Takeda JPY 4.85T 208B Dec/2025
Ultragenyx Pharmaceutical USD 36M 2.17M Dec/2025
Vanda Pharmaceuticals USD 4.96M 4.96M Dec/2024